证券之星消息，截至2026年2月26日收盘，美好医疗(301363)报收于30.1元，下跌8.76%，换手率 6.05%，成交量22.58万手，成交额6.91亿元。 2月26日的资金流向数据方面，主力资金净流出8423.1万元，占总成交额12.18%，游资资金净流入 485.49万元，占总成交额0.7%，散户资金净流入7937.61万元，占总成交额11.48%。 近5日资金流向一览见下表： 美好医疗融资融券信息显示，融资方面，当日融资买入6080.5万元，融资偿还7133.63万元，融资净偿还 1053.13万元。融券方面，融券卖出4000.0股，融券偿还2300.0股，融券余量6.34万股，融券余额190.77 万元。融资融券余额2.94亿元。 该股主要指标及行业内排名如下： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 92 ...

Group 1 - In February, nearly 240 listed companies were surveyed by various institutions, with over half achieving positive returns during the same period, and some stocks seeing cumulative gains exceeding 80% [1] - The mechanical equipment and electronics sectors were the primary focus of institutional surveys, with significant attention also given to cyclical sectors like basic chemicals [1] - Institutions are optimistic about investment opportunities in humanoid robots, upstream AI infrastructure, and certain chemical sector stocks that offer high elasticity and dividends [1] Group 2 - In January 2026, domestic automobile sales reached 2.346 million units, with the top ten companies accounting for 1.962 million units, representing 83.6% of total sales, indicating a high concentration in the market [2] - The automotive market is characterized by "steady start and structural differentiation," with increased competition among top manufacturers as they launch new products and technologies [2] - The pharmaceutical and biotechnology sectors saw 80 companies receive institutional surveys, with a focus on brain-computer interface stocks and the trend of innovative drugs going global [2] Group 3 - Several securities firms have held spring strategy meetings earlier than usual, reflecting changes in the competitive landscape of the industry [3] - The shift from "commission for research" to "service for income" is becoming more pronounced among brokerage firms [3] - The AI industry is entering a more pragmatic phase, focusing on revenue and profit, with significant investment opportunities in AI inference computing and domestic AI chips [3] Group 4 - Lithium carbonate futures surged by 11.83% to a high of 187,700 yuan/ton, driven by Zimbabwe's adjustments to lithium export policies, which may tighten global supply in the short term [4] - UBS predicts a potential third price cycle for lithium, raising the average price expectation for 2026 to around 180,000 yuan/ton [4] Group 5 - The A-share merger and acquisition market remains vibrant, with over 500 transactions disclosed since the beginning of the year, totaling over 100 billion yuan [5] - More than 50% of these transactions are driven by industrial synergy, highlighting a core market trend [5] - The hard technology sector is a primary battleground for mergers and acquisitions, with increased participation from the Sci-Tech Innovation Board and the Growth Enterprise Market [5] Group 6 - The Hong Kong Stock Exchange reported record highs in trading volume and revenue for 2025, reaffirming its position as a global leader in new stock financing [6] - The exchange aims to enhance market convenience and competitiveness while continuing to invest strategically in emerging business areas [6] - Export-oriented companies are actively implementing measures to hedge against currency risks amid fluctuations in the renminbi exchange rate [6] Group 7 - Regions like Guangdong, Anhui, and Hubei are strategically positioning themselves in advanced fields such as AI, quantum technology, and high-end manufacturing [7] - The development of future industries relies heavily on original innovation and disruptive technologies, which are still in early stages [7] - Policies are increasingly systematic and comprehensive, supporting innovation from inception to market application [7] Group 8 - NIO's chip subsidiary, Anhui Shenji Technology Co., completed its first round of equity financing, raising 2.257 billion yuan, with a post-investment valuation nearing 10 billion yuan [8] - The financing attracted diverse capital participation, including state-owned capital and semiconductor industry funds, indicating market confidence in the company's technology and production capabilities [8] - The involvement of local state capital aligns with Hefei's ongoing investment in the integrated circuit industry [8]

Core Insights - The pharmaceutical and biotechnology sector is experiencing increased institutional interest, particularly in brain-computer interface (BCI) stocks, driven by advancements in technology and commercialization efforts [1][2][3] Group 1: Brain-Computer Interface (BCI) Stocks - BCI stocks such as Xiangyu Medical, Aipeng Medical, and Meihao Medical have attracted significant institutional attention, with Xiangyu Medical receiving 208 institutional inquiries, Aipeng Medical 177, and Meihao Medical 125 [1] - Xiangyu Medical plans to upgrade 27 core products by mid-2026 and aims to launch nearly 100 BCI products by the end of 2026, focusing on multi-modal and multi-paradigm applications [2] - Aipeng Medical emphasizes the rapid growth of the BCI industry, particularly in non-invasive applications, and is prioritizing commercialization strategies based on existing technologies and channels [2] - Meihao Medical aims to be a key supplier in the BCI field, enhancing its competitive edge in invasive BCI implants through increased R&D investment and collaboration with clients [2][3] Group 2: Globalization of Pharmaceutical Companies - Domestic pharmaceutical companies are focusing on global strategies, with an emphasis on the commercialization of innovative drugs abroad [4][5] - MediXis has established a 2,000 square meter R&D office in Boston to support its global strategy, with overseas revenue expected to account for approximately 47% of total income by 2025 [4] - Huayuan Pharmaceutical has set up multiple business and R&D centers globally, with overseas revenue reaching 43% of total income in the first half of 2025 [4][5] - The "innovation + internationalization" strategy remains a core focus for the sector, with increasing participation of Chinese companies in global pharmaceutical collaborations [6]

证券研究报告 把握AI主线，重视新科技 ——计算机行业2026春季投资策略 行业投资评级：强于大市|维持 孙业亮/刘聪颖 中邮证券研究所 计算机团队 中邮证券 1 1 发布时间：2026-02-25 投资要点 AI大模型：2025年，中国AI大模型产品形态进入成熟期，成为市场爆发的直接推动力，低成本、高性能 的技术基础形成了从底层支撑市场高速增长的关键条件，为MaaS和企业大模型的广泛应用创造了可持续 的商业化环境；多模态模型的快速迭代将AI应用从单一文本生成扩展至图像、视频、语音等复合场景，提 升了模型的可用性与商业化潜力；同时，各大厂商通过推出通用基座模型、行业专属模型及低门槛API服 务，构建了完整的产品矩阵，极大降低了企业和开发者的接入成本；企业对AI价值的认知日益成熟，数字 化和智能化转型需求持续增长，推动客户需求从概念验证阶段进入规模化生产阶段，企业对于大模型的调 用频次和覆盖场景不断增加，从而带动MaaS平台和AI大模型解决方案市场进入了"结构性放量"周期。 AI应用：toB端，AI Agent是大模型重要的商业落地形式，已在客服、代码开发、营销、数据分析、金 融服务等多行业、多场景实现服务落地 ...

该股主要指标及行业内排名如下： 美好医疗融资融券信息显示，融资方面，当日融资买入5743.01万元，融资偿还3516.2万元，融资净买入 2226.81万元。融券方面，融券卖出7600.0股，融券偿还6000.0股，融券余量5.9万股，融券余额193.81万 元。融资融券余额2.98亿元。 近5日融资融券数据一览见下表： 证券之星消息，截至2026年2月24日收盘，美好医疗(301363)报收于32.86元，下跌5.79%，换手率 4.54%，成交量16.93万手，成交额5.55亿元。 2月24日的资金流向数据方面，主力资金净流出4036.56万元，占总成交额7.28%，游资资金净流入 2331.2万元，占总成交额4.2%，散户资金净流入1705.35万元，占总成交额3.08%。 近5日资金流向一览见下表： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5. ...

证券之星消息，截至2026年2月13日收盘，美好医疗(301363)报收于34.88元，上涨6.57%，换手率 6.75%，成交量25.19万手，成交额8.6亿元。 2月13日的资金流向数据方面，主力资金净流入1.13亿元，占总成交额13.19%，游资资金净流入3679.75 万元，占总成交额4.28%，散户资金净流出1.5亿元，占总成交额17.47%。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 该股最近90天内共有4家机构给出评级，买入评级4家； ...

Group 1 - In January, a total of 35 companies had more than 50 research institutions and over 10 rating agencies involved [1] - Dajin Heavy Industry received the highest attention with 318 research institutions conducting investigations [1] - Among rating agencies, Zhongji Xuchuang topped the list with 34 ratings from different institutions [1] Group 2 - Three bank stocks, Jiangsu Bank, Shanghai Bank, and Nanjing Bank, made it to the list, with Jiangsu Bank receiving investigations from as many as 133 institutions [1] - The average increase in stock prices for the listed companies this year has exceeded 16%, significantly outperforming the broader market [1] - Notable stocks such as Dike Co., Caibai Co., Jiemai Technology, and Meihao Medical have all seen increases of over 40% [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology sector is "Outperform the Market" (maintained) [2] Core Insights - The pharmaceutical sector underperformed the market in Q4 2025, with the overall sector down by 9.3% compared to a slight decline of 0.2% in the CSI 300 index. Notably, the pharmaceutical commercial segment showed a positive performance with a 5.3% increase, while other segments like medical services and biological products experienced significant declines [4][8] - The total net asset value of pharmaceutical funds decreased to 358.4 billion yuan, a 9.0% decline quarter-on-quarter. This marks the first time since 2019 that passive pharmaceutical funds (181.8 billion yuan) surpassed active funds (176.5 billion yuan) [4][14] - The overall pharmaceutical holdings across all funds dropped to 7.97%, a decrease of 1.71 percentage points. Active pharmaceutical funds maintained a high concentration with a holding ratio of 97.45% [23] Summary by Sections 1. Market Review - In Q4 2025, the pharmaceutical and biotechnology sector lagged behind the CSI 300 index, with a decline of 9.3%. The chemical pharmaceuticals segment fell by 9.6%, biological products by 12.4%, and medical devices by 10.6% [8] 2. Pharmaceutical Fund Size - As of Q4 2025, the net asset value of pharmaceutical funds was 358.4 billion yuan, down 9.0% from the previous quarter. Active funds accounted for 176.5 billion yuan, a 14.6% decrease, while passive funds reached 181.8 billion yuan, down 2.8% [14] 3. Pharmaceutical Holdings Ratio - The pharmaceutical holdings ratio for all funds was 7.97%, down 1.71 percentage points. Active pharmaceutical funds had a holding ratio of 97.08%, while passive funds had 97.83% [23] 4. Holdings Structure Analysis - The highest sub-sector holding in Q4 2025 was chemical preparations at 37.5%, followed by other biological products at 20.8%. The largest increases in holdings were seen in traditional Chinese medicine (+0.98 percentage points) and chemical preparations (+0.62 percentage points) [29] 5. Additions and Reductions in Holdings - The top three pharmaceutical stocks by the number of funds holding them were Heng Rui Medicine (498 funds), WuXi AppTec (408 funds), and Mindray Medical (204 funds). Notably, Heng Rui Medicine saw a reduction of 236 funds, while Ying En Biological-B experienced an increase of 47 funds [84][88]

Core Insights - The article highlights the increasing focus of institutional investors on hard technology breakthroughs and performance certainty for investment opportunities in 2026 [4] Group 1: Institutional Research Trends - In late 2025 to early 2026, institutions conducted research on approximately 1,162 companies, with a total of 30,000 receptions from listed companies across various core industries [3] - The shift in focus from merely gathering data to understanding practical applications indicates a significant change in investment strategies [9] Group 2: Brain-Computer Interface (BCI) Focus - Brain-computer interface technology has emerged as a key area of interest, with companies like Xiangyu Medical, Aipeng Medical, and Meihao Medical frequently hosting inquiries from fund managers [5][6] - Institutions are particularly interested in the depth of collaboration with innovative BCI clients and the feasibility of mass production [7][8] Group 3: AI Computing Power and Applications - The focus on artificial intelligence has shifted from foundational models to the iteration of computing power and practical applications [10] - Companies like Zhongji Xuchuang attracted attention for their 1.6T optical module orders and technology advancements, reflecting a market shift towards evaluating technological iteration speed [10] Group 4: Commercial Aerospace and Semiconductor Focus - Commercial aerospace has gained significant attention, with institutions exploring various segments such as rocket manufacturing and satellite components [17] - In the semiconductor sector, institutions are focused on overcoming technical barriers, with companies like Haimei Information and Huaren Micro receiving extensive inquiries regarding their advanced process products [22][23] - The trend of institutions closely monitoring companies with promising earnings forecasts indicates a more rational investment approach, seeking high-quality targets with core competitiveness [26]

Core Viewpoint - The company, 美好医疗, has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Performance - 美好医疗's stock rose by 6.57% with a trading volume of 860 million yuan and a turnover rate of 6.75%, leading to a total market capitalization of 19.842 billion yuan [1]. - The company reported a revenue of 1.194 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% [7][8]. - The company has a significant overseas revenue contribution, accounting for 86.64% of total revenue, benefiting from the depreciation of the yuan [3]. Group 2: Business Operations - 美好医疗 is engaged in the design, development, manufacturing, and sales of precision components and products in the medical device sector, with a focus on home respiratory machine components, cochlear implant components, and pulmonary function instruments [2][7]. - The company is actively collaborating with downstream brain-machine interface clients to facilitate efficient commercialization from laboratory research to mass production, although current revenue from this segment is still small [2]. - 美好医疗 has initiated the construction of automated production lines for weight loss pen orders, expected to be delivered next year [2]. Group 3: Market Dynamics - The company is categorized under the medical device sector, with its main products including home respiratory machine components (59.48% of revenue), consumer electronics components (14.61%), and other medical product components [7]. - The stock has shown signs of accumulation, with an average trading cost of 32.84 yuan, and is approaching a resistance level of 35.00 yuan, indicating potential for upward movement if this level is breached [6].